Favorable safety and efficacy profile observed at 6 months and 1 year persisted at 2-year follow-up, demonstrating that the use of the Taxus stent prevents, rather than delays, in-stent restenosis.

EuroPCR 2006: "The TAXUS VI trial shows us that the TAXUS MR stent is extremely effective in treating high-risk patients with very complex lesions, and the results are sustained over the long term." ...

Key Results from the SPIRIT IV Trial. In the SPIRIT IV trial of 3,690 patients, XIENCE V demonstrated the following key results at two years: A 30 percent risk reduction in TLF compared to TAXUS ...

The FDA said it is investigating problems with Boston Scientific's Taxus stent after a Michigan hospital suspended use of the devices. William Beaumont Hospital in Royal Oak stopped using the ...